
H Bristol Myers Squibb™



Are you the parent of a 12 to 17-year-old with moderate-to-severe plaque psoriasis?



Research study IM011-126 Part A is evaluating the safety and tolerability of the study drug deucravacitinib in treating children with moderate-to-severe plaque psoriasis.

Your child may be eligible if he or she has moderate-to-severe plaque psoriasis and:

- Is 12 to 17 years of age
- Is able to swallow study medication
- Has been showing symptoms of plaque psoriasis for 6 months or more

For more information about the IM011-126 research study, ask your doctor or contact the research team below:

 Has been diagnosed with moderate-to-severe plaque psoriasis*

The study doctor will also check other requirements to decide if your patient is eligible to take part in this study.

If eligible, your child may receive⁺:

- Study-related medical care
- Study-related lab work and procedures

Site Staff: Include your site's contact information in the box.



*Can be moderate-to-severe for less than 6 months.

⁺Depending on where you live, some medical care may be charged to you or your insurance. Please discuss specifics with the study staff.

© 2021 Bristol-Myers Squibb Company. 172021013-UK 11/2021 [22433]